Xenon Pharmaceuticals Inc Working Capital to Net Assets Ratio
Xenon Pharmaceuticals Inc working capital to net assets ratio. Xenon Pharmaceuticals Inc (XENE) has a Working Capital to Net Assets ratio of 89.2% as of December 2025. Working capital of $518.86 Million (current assets of $560.65 Million minus current liabilities of $41.79 Million) is measured against net assets of $581.76 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Xenon Pharmaceuticals Inc (2012–2025)
Working capital to net assets ratio of Xenon Pharmaceuticals Inc from 2012 to 2025. This chart shows how Xenon Pharmaceuticals Inc's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of December 2025, the ratio stands at 89.2%, reflecting working capital of $518.86 Million against net assets of $581.76 Million USD. Explore Xenon Pharmaceuticals Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Xenon Pharmaceuticals Inc Working Capital to Net Assets Ratio by Year (2012–2025)
Xenon Pharmaceuticals Inc working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Xenon Pharmaceuticals Inc from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see XENE current and non-current assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 89.2% | $518.86 Million | $581.76 Million | $560.65 Million | $41.79 Million | ▲ +9.8 pp |
| 2024 | 79.4% | $599.67 Million | $754.90 Million | $635.26 Million | $35.59 Million | ▲ +12.9 pp |
| 2023 | 66.6% | $617.69 Million | $927.92 Million | $644.96 Million | $27.27 Million | ▼ -13.5 pp |
| 2022 | 80.1% | $577.60 Million | $721.50 Million | $600.30 Million | $22.70 Million | ▼ -19.0 pp |
| 2021 | 99.0% | $544.70 Million | $550.03 Million | $559.02 Million | $14.32 Million | ▲ +1.6 pp |
| 2020 | 97.5% | $167.00 Million | $171.35 Million | $181.78 Million | $14.78 Million | ▼ -12.9 pp |
| 2019 | 110.3% | $101.49 Million | $91.98 Million | $144.87 Million | $43.38 Million | ▼ -3.2 pp |
| 2018 | 113.6% | $117.32 Million | $103.30 Million | $121.44 Million | $4.12 Million | ▲ +0.2 pp |
| 2017 | 113.4% | $40.74 Million | $35.93 Million | $44.82 Million | $4.08 Million | ▲ +16.1 pp |
| 2016 | 97.3% | $62.16 Million | $63.90 Million | $65.67 Million | $3.52 Million | ▲ +2.1 pp |
| 2015 | 95.2% | $58.08 Million | $61.03 Million | $60.87 Million | $2.78 Million | ▼ -1.9 pp |
| 2014 | 97.1% | $70.66 Million | $72.78 Million | $84.94 Million | $14.29 Million | ▼ -34.2 pp |
| 2013 | 131.3% | $31.67 Million | $24.12 Million | $49.87 Million | $18.20 Million | ▼ -197.5 pp |
| 2012 | 328.8% | $41.51 Million | $12.62 Million | $60.70 Million | $19.20 Million | — |